NCT06035614

Efficacy and Safety of 308-nm Excimer Lamp Combined With Tacrolimus vs Tacrolimus as Monotherapy in Treating Vitiligo on Children

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Clarteis · Industry
• Sex: All
• Age: 4 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

Vitiligo is a auto immune that impact 2% of the global population, regardless from the phototype. Even though it affects patients in a physical way through loss of pigmentation, it is also impacting them on a mental/emotional way.11-12 Current treatments offer a symptomatic solution to patients, however the response rate can be low and results can be slow. Pediatric patients in vitiligo deserves special care as frequently (50%), the disease onset is before 20 years of age and, in 25% of the cases, it starts before the age of 10 years.13 Also, the current treatments for children are limited since it can involve pain and claustrophobia. The combination therapy of the study could offer a painless and easy treatment to follow. If the combination of those two therapies can fasten and improve the response rate, this could be a good option to treat this condition not only in children, but also for adults patients.

Conditions

• Vitiligo
• Pediatric ALL
• Dermatologic Disease
• Autoimmune Diseases

Interventions

Type	Name	Description
DEVICE	exciplex	exciplex, excimer lamp 308nm produced by clarteis
DRUG	Tacrolimus ointment	tacrolimus monohydrate ointment 0.1% TACRUS

Timeline

• Start date: 2022-10-01
• Primary completion: 2023-05-01
• Completion: 2023-07-01
• First posted: 2023-09-13
• Last updated: 2023-09-13

Locations

1 site across 1 country: Jordan